---
layout: post
title: "Advancing the Development of Pediatric Therapeutics on Drug Dosing in Pediatric Patients With Renal Impairment; Public Workshop"
date: 2026-02-05 18:56:57 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-20903
original_published: 2023-09-26 00:00:00 +0000
significance: 8.00
---

# Advancing the Development of Pediatric Therapeutics on Drug Dosing in Pediatric Patients With Renal Impairment; Public Workshop

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 26, 2023 00:00 UTC
**Document Number:** 2023-20903

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Advancing the Development of Pediatric Therapeutics (ADEPT 8) on Drug Dosing in Pediatric Patients With Renal Impairment." The purpose of the public workshop is to discuss the current landscape of drug dosing in pediatric patients with renal impairment, understand the gaps in knowledge, and consider innovative approaches to improve the current paradigm for dosing in pediatric patients with renal impairment.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/26/2023-20903/advancing-the-development-of-pediatric-therapeutics-on-drug-dosing-in-pediatric-patients-with-renal)
- API: https://www.federalregister.gov/api/v1/documents/2023-20903

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
